WO2002011762A3 - Methods and compositions for modulating tumor growth - Google Patents

Methods and compositions for modulating tumor growth Download PDF

Info

Publication number
WO2002011762A3
WO2002011762A3 PCT/CA2001/001111 CA0101111W WO0211762A3 WO 2002011762 A3 WO2002011762 A3 WO 2002011762A3 CA 0101111 W CA0101111 W CA 0101111W WO 0211762 A3 WO0211762 A3 WO 0211762A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tumor growth
compositions
modulating tumor
administered
Prior art date
Application number
PCT/CA2001/001111
Other languages
French (fr)
Other versions
WO2002011762A2 (en
Inventor
Reginald M Gorczynski
David A Clark
Original Assignee
Reginald M Gorczynski
David A Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reginald M Gorczynski, David A Clark filed Critical Reginald M Gorczynski
Priority to AU2001278338A priority Critical patent/AU2001278338A1/en
Priority to CA2417874A priority patent/CA2417874C/en
Publication of WO2002011762A2 publication Critical patent/WO2002011762A2/en
Publication of WO2002011762A3 publication Critical patent/WO2002011762A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions for regulating tumor growth are disclosed. For reducing tumor growth, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For enhancing tumor growth, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in studying cancer and/or tumor metastasis.
PCT/CA2001/001111 2000-08-03 2001-07-30 Methods and compositions for modulating tumor growth WO2002011762A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001278338A AU2001278338A1 (en) 2000-08-03 2001-07-30 Methods and compositions for modulating tumor growth
CA2417874A CA2417874C (en) 2000-08-03 2001-07-30 Use of ox-2 inhibitors for the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22272500P 2000-08-03 2000-08-03
US60/222,725 2000-08-03

Publications (2)

Publication Number Publication Date
WO2002011762A2 WO2002011762A2 (en) 2002-02-14
WO2002011762A3 true WO2002011762A3 (en) 2003-03-13

Family

ID=22833418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001111 WO2002011762A2 (en) 2000-08-03 2001-07-30 Methods and compositions for modulating tumor growth

Country Status (3)

Country Link
AU (1) AU2001278338A1 (en)
CA (1) CA2417874C (en)
WO (1) WO2002011762A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513660A (en) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド Cutting type CD200
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP4280803B2 (en) 2000-12-08 2009-06-17 アレクシオン ファーマシューティカルズ， インコーポレイテッド Chronic lymphocytic leukemia cell line and its use for producing antibodies
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
DK1482973T3 (en) * 2002-03-15 2009-12-07 Schering Corp Method for modulating CD200 receptors
CA2511513A1 (en) * 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
AU2012211347B9 (en) * 2004-07-20 2015-06-18 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
DK2463305T3 (en) 2006-01-12 2016-08-29 Alexion Pharma Inc Antibodies to OX-2 / CD200 and uses thereof
KR20100036362A (en) 2007-07-25 2010-04-07 알렉시온 파마슈티칼스, 인코포레이티드 Methods and compositions for treating autoimmune disease
US9180186B2 (en) 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
CN109475603B (en) 2016-06-20 2023-06-13 科马布有限公司 anti-PD-L1 antibodies
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-cd200 therapy
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024565A1 (en) * 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024565A1 (en) * 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. NI ET AL.: "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant which prolongs allograft survival.", THE FASEB JOURNAL, vol. 13, no. 5, 15 March 1999 (1999-03-15), Bethesda, MD, USA, pages A983, XP000960581 *
R. RAGHEB ET AL.: "Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2.", IMMUNOLOGY LETTERS, vol. 68, no. 2-3, 1 June 1999 (1999-06-01), Amsterdam, The Netherlands, pages 311 - 315, XP000960642 *

Also Published As

Publication number Publication date
AU2001278338A1 (en) 2002-02-18
CA2417874C (en) 2012-10-02
CA2417874A1 (en) 2002-02-14
WO2002011762A2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
WO2002011762A3 (en) Methods and compositions for modulating tumor growth
WO2001064246A3 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
WO2003014303A3 (en) Molecular interactions in cells
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
WO2003045309A3 (en) Peptides, peptide compositions,and methods of use in binding p 185
WO2002044376A3 (en) Modulation of gene expression using insulator binding proteins
AU4100199A (en) Compositions and methods for enhancing protein anabolism and detoxification
HK1049185A1 (en) Modified fluorescent proteins
EP1351573A4 (en) Methods for modulating tumor growth and metastasis
AU2001263269A1 (en) Long wavelength engineered fluorescent proteins
AU2002311859A1 (en) Compositions and methods for treating colorectal polyps and cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001053524A3 (en) Cancer associated genes and their products
WO2003000901A3 (en) Nucleic acids encoding protein kinases
WO2003030719A3 (en) Methods and kits for use in selecting approaches to treating cancer
WO2002026960A3 (en) Modulation of gene expression using localization domains
WO1999047709A3 (en) Methods for identifying anti-cancer agents
EP1273296A3 (en) Combination chemotherapy
WO2005002509A3 (en) Dna vectors
EP1045914B8 (en) Testis-specific human svph1-8 proteinase
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2004000999A3 (en) Identification of a receptor controlling migration and metastasis of skin cancer cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2417874

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP